The ability of adenoviral vectors to direct long term transgene expression continues to be hampered by both the host immune response on the vector as well as the nonimmune mediated loss of vector genomes.
Not long ago an easy protocol was described involving a single dose of dexamethasone that demonstrated decreased innate and adaptive immune responses, whilst simultaneously staying away from adenovirus stimulated thrombocytopenia and leukocyte infiltration. histone deacetylase inhibitor Systemic administration of helper dependent vector is still further complicated by the potential liver toxicity and transient thrombocytopenia as observed in canine models of hemophilia. This toxicity can be minimized by local delivery using balloon occlusion catheters as has been shown in a NHP model. Recent findings in a clinical trial in which an AAV vector expressing human FIX was introduced into the liver of hemophilia B subjects revealed an unanticipated rejection of transduced hepatocytes mediated by AAV2 capsid specific CD8 T cells. Notably, neither a CD8 T cell response nor formation of antibody to FIX were ever detected.
In an attempt to avoid vector capsid mediated immune responses, a short course of MMF and cyclosporine was administered for 12 weeks. In this study, transient IS was safe and effective in preventing or delaying antivector T cell responses. To date, preclinical studies in several species failed PARP to predict and to reproduce the findings of vector capsid cellular immune responses. Thus, the efficacy of a IS regimen to prevent this complication cannot be properly addressed in preclinical studies. However, the overall safety of the IS coupled with AAV vectors is feasible, notably in data obtained in NHP models. Two studies on IS regimens consisted of MMF with tacrolimus or MMF and rapamycin over a period of 10 weeks.
The role of T reg cells in other tissue targets by AAV vectors is not yet determined. However, it is possible to induce transgene specific T regulatory cells by liver restricted expression that suppress cellular immune responses in strategies that otherwise are hampered by strong immune responses.
Wednesday, March 27, 2013
Everything Most People Know About histone deacetylase inhibitor IEM 1754 Is Wrong
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment